Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 5;6(4):e60.
doi: 10.1192/bjo.2020.43.

Inflammation as a treatment target in mood disorders: review

Brett D M Jones  1 , Zafiris J Daskalakis  1 , Andre F Carvalho  1 , Rebecca Strawbridge  2 , Allan H Young  2 , Benoit H Mulsant  1 , M Ishrat Husain  1
Affiliations

Inflammation as a treatment target in mood disorders: review

Brett D M Jones et al. BJPsych Open. .

Abstract

Background: Mood disorders, i.e. major depressive disorder (MDD) and bipolar disorders, are leading sources of disability worldwide. Currently available treatments do not yield remission in approximately a third of patients with a mood disorder. This is in part because these treatments do not target a specific core pathology underlying these heterogeneous disorders. In recent years, abnormal inflammatory processes have been identified as putative pathophysiological mechanisms and treatment targets in mood disorders, particularly among individuals with treatment-resistant conditions.

Aims: In this selective review, we aimed to summarise recent advances in the field of immunopsychiatry, including emerging pathophysiological models and findings from treatment ttrials of immunomodulatory agents for both MDD and bipolar disorders.

Method: We performed a literature review by searching Medline for clinical trials of immunomodulating agents as monotherapy or adjunctive treatments in MDD and bipolar disorders. Included studies are randomised controlled trials (RCTs), cluster RCTs or cross-over trials of immunomodulating agents that had an active comparator or a placebo-arm.

Results: Current evidence shows an association between inflammation and mood symptoms. However, there is conflicting evidence on whether this link is causal.

Conclusions: Future studies should focus on identifying specific neurobiological underpinnings for the putative causal association between an activated inflammatory response and mood disorders. Results of these studies are needed before further treatment trials of immunomodulatory agents can be justified.

Keywords: Depressive disorders; antidepressants; bipolar affective disorders; neuroimmunology; novel CNS drugs.

PubMed Disclaimer

Conflict of interest statement

Supplementary material

Figures

Fig. 1
Fig. 1
Inflammation and mood disorders.
See this image and copyright information in PMC

References

    1. World Health Organization. WHO Global Burden of Disease (2008): 2004 Update. WHO, 2008.
    1. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. WHO, 2017.
    1. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003. Dec; 64: 1465–75. - PubMed
    1. Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat 2017; 13: 1245–62. - PMC - PubMed
    1. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748–51. - PubMed